Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...

Morocco’s Ministry of Health and Social Protection has confirmed that no epidemic outbreaks have been recorded following the ...

Construction of both stations is set to begin in the second quarter of 2026, with passenger service projected to start in 2035.

Wilding Gold Project (~5,000m planned): Initial field program consisting of ~250 percussion drill holes (basal till and ...

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events .

AI agents are popping up everywhere, but without a conductor, they clash, waste money and create more problems than they ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

SHANNON, CLARE, IRELAND, February 5, 2026 /EINPresswire.com/ -- A new publication from Opto-Electronic Technology; DOI ...

Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.

Competing with giants like Takeda and Moderna, the plucky biotech believes it has unlocked a future with an easy, yearly oral vaccine.

Phase III is designed to test the continuity of the Southwick gold-silver vein corridor beyond the Rosebud Mine, supported by the Company's recently completed 3D Magnetic Vector Inversion (MVI) model ...